Literature DB >> 21345945

The gut mucosal viral reservoir in HIV-infected patients is not the major source of rebound plasma viremia following interruption of highly active antiretroviral therapy.

Paula Lerner1, Moraima Guadalupe, Richard Donovan, Jason Hung, Jason Flamm, Thomas Prindiville, Sumathi Sankaran-Walters, Michael Syvanen, Joseph K Wong, Michael D George, Satya Dandekar.   

Abstract

Interruption of suppressive highly active antiretroviral therapy (HAART) in HIV-infected patients leads to increased HIV replication and viral rebound in peripheral blood. Effects of therapy interruption on gut-associated lymphoid tissue (GALT) have not been well investigated. We evaluated longitudinal changes in viral replication and emergence of viral variants in the context of T cell homeostasis and gene expression in GALT of three HIV-positive patients who initiated HAART during primary HIV infection but opted to interrupt therapy thereafter. Longitudinal viral sequence analysis revealed that a stable proviral reservoir was established in GALT during primary HIV infection that persisted through early HAART and post-therapy interruption. Proviral variants in GALT and peripheral blood mononuclear cells (PBMCs) displayed low levels of genomic diversity at all times. A rapid increase in viral loads with a modest decline of CD4(+) T cells in peripheral blood was observed, while gut mucosal CD4(+) T cell loss was severe following HAART interruption. This was accompanied by increased mucosal gene expression regulating interferon (IFN)-mediated antiviral responses and immune activation, a profile similar to those found in HAART-naive HIV-infected patients. Sequence analysis of rebound virus suggested that GALT was not the major contributor to the postinterruption plasma viremia nor were GALT HIV reservoirs rapidly replaced by HIV rebound variants. Our data suggest an early establishment and persistence of viral reservoirs in GALT with minimal diversity. Early detection of and therapy for HIV infection may be beneficial in controlling viral evolution and limiting establishment of diverse viral reservoirs in the mucosal compartment.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21345945      PMCID: PMC3126205          DOI: 10.1128/JVI.02409-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  46 in total

1.  Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy.

Authors:  D Finzi; J Blankson; J D Siliciano; J B Margolick; K Chadwick; T Pierson; K Smith; J Lisziewicz; F Lori; C Flexner; T C Quinn; R E Chaisson; E Rosenberg; B Walker; S Gange; J Gallant; R F Siliciano
Journal:  Nat Med       Date:  1999-05       Impact factor: 53.440

2.  Emergence of drug-resistant HIV-1 variants in patients undergoing structured treatment interruptions.

Authors:  Becky Schweighardt; Gabriel M Ortiz; Robert M Grant; Melissa Wellons; G Diego Miralles; Leondios G Kostrikis; John A Bartlett; Douglas F Nixon
Journal:  AIDS       Date:  2002-11-22       Impact factor: 4.177

3.  HIV rebounds from latently infected cells, rather than from continuing low-level replication.

Authors:  Beda Joos; Marek Fischer; Herbert Kuster; Satish K Pillai; Joseph K Wong; Jürg Böni; Bernard Hirschel; Rainer Weber; Alexandra Trkola; Huldrych F Günthard
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-20       Impact factor: 11.205

4.  Human immunodeficiency virus type 1 quasi species that rebound after discontinuation of highly active antiretroviral therapy are similar to the viral quasi species present before initiation of therapy.

Authors:  H Imamichi; K A Crandall; V Natarajan; M K Jiang; R L Dewar; S Berg; A Gaddam; M Bosche; J A Metcalf; R T Davey ; H C Lane
Journal:  J Infect Dis       Date:  2000-12-08       Impact factor: 5.226

5.  Genetic characterization of rebounding human immunodeficiency virus type 1 in plasma during multiple interruptions of highly active antiretroviral therapy.

Authors:  Mark Dybul; Marybeth Daucher; Mark A Jensen; Claire W Hallahan; Tae-Wook Chun; Michael Belson; Bertha Hidalgo; David C Nickle; Christian Yoder; Julia A Metcalf; Richard T Davey; Linda Ehler; Diane Kress-Rock; Elizabeth Nies-Kraske; Shuying Liu; James I Mullins; Anthony S Fauci
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

6.  Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy.

Authors:  Steven A Yukl; Sara Gianella; Elizabeth Sinclair; Lorrie Epling; Qingsheng Li; Lijie Duan; Alex L M Choi; Valerie Girling; Terence Ho; Peilin Li; Katsuya Fujimoto; Harry Lampiris; C Bradley Hare; Mark Pandori; Ashley T Haase; Huldrych F Günthard; Marek Fischer; Amandeep K Shergill; Kenneth McQuaid; Diane V Havlir; Joseph K Wong
Journal:  J Infect Dis       Date:  2010-10-12       Impact factor: 5.226

7.  Rapid onset of intestinal epithelial barrier dysfunction in primary human immunodeficiency virus infection is driven by an imbalance between immune response and mucosal repair and regeneration.

Authors:  Sumathi Sankaran; Michael D George; Elizabeth Reay; Moraima Guadalupe; Jason Flamm; Thomas Prindiville; Satya Dandekar
Journal:  J Virol       Date:  2007-10-24       Impact factor: 5.103

8.  Male genital tract compartmentalization of human immunodeficiency virus type 1 (HIV).

Authors:  Kurt Diem; David C Nickle; Alexis Motoshige; Alan Fox; Susan Ross; James I Mullins; Lawrence Corey; Robert W Coombs; John N Krieger
Journal:  AIDS Res Hum Retroviruses       Date:  2008-04       Impact factor: 2.205

9.  Simian immunodeficiency virus (SIV) envelope quasispecies transmission and evolution in infant rhesus macaques after oral challenge with uncloned SIVmac251: increased diversity is associated with neutralizing antibodies and improved survival in previously immunized animals.

Authors:  Jennifer L Greenier; Koen K A Van Rompay; David Montefiori; Patricia Earl; Bernard Moss; Marta L Marthas
Journal:  Virol J       Date:  2005-02-14       Impact factor: 4.099

10.  Low human immunodeficiency virus envelope diversity correlates with low in vitro replication capacity and predicts spontaneous control of plasma viremia after treatment interruptions.

Authors:  Beda Joos; Alexandra Trkola; Marek Fischer; Herbert Kuster; Peter Rusert; Christine Leemann; Jürg Böni; Annette Oxenius; David A Price; Rodney E Phillips; Joseph K Wong; Bernard Hirschel; Rainer Weber; Huldrych F Günthard
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

View more
  44 in total

Review 1.  HIV reservoirs and strategies for eradication.

Authors:  Miranda Z Smith; Fiona Wightman; Sharon R Lewin
Journal:  Curr HIV/AIDS Rep       Date:  2012-03       Impact factor: 5.071

2.  Origin of Rebound Plasma HIV Includes Cells with Identical Proviruses That Are Transcriptionally Active before Stopping of Antiretroviral Therapy.

Authors:  Mary F Kearney; Ann Wiegand; Wei Shao; John M Coffin; John W Mellors; Michael Lederman; Rajesh T Gandhi; Brandon F Keele; Jonathan Z Li
Journal:  J Virol       Date:  2015-11-18       Impact factor: 5.103

3.  The majority of HIV type 1 DNA in circulating CD4+ T lymphocytes is present in non-gut-homing resting memory CD4+ T cells.

Authors:  Kristin McBride; Yin Xu; Michelle Bailey; Nabila Seddiki; Kazuo Suzuki; John M Murray; Yuan Gao; Celine Yan; David A Cooper; Anthony D Kelleher; Kersten K Koelsch; John Zaunders
Journal:  AIDS Res Hum Retroviruses       Date:  2013-10       Impact factor: 2.205

Review 4.  HIV-1 transcription and latency: an update.

Authors:  Carine Van Lint; Sophie Bouchat; Alessandro Marcello
Journal:  Retrovirology       Date:  2013-06-26       Impact factor: 4.602

5.  CCR5 expression is reduced in lymph nodes of HIV type 1-infected women, compared with men, but does not mediate sex-based differences in viral loads.

Authors:  Amie L Meditz; Joy M Folkvord; Ngan H Lyle; Kristina Searls; Yolanda S Lie; Eoin P Coakley; Martin McCarter; Samantha Mawhinney; Elizabeth Connick
Journal:  J Infect Dis       Date:  2013-10-31       Impact factor: 5.226

6.  Phylogenetic Analyses Comparing HIV Sequences from Plasma at Virologic Failure to Cervix Versus Blood Sequences from Antecedent Antiretroviral Therapy Suppression.

Authors:  Marta E Bull; Jennifer L McKernan; Sheila Styrchak; Kelli Kraft; Jane Hitti; Susan E Cohn; Kenneth Tapia; Wenjie Deng; Sarah Holte; James I Mullins; Robert W Coombs; Lisa M Frenkel
Journal:  AIDS Res Hum Retroviruses       Date:  2019-04-30       Impact factor: 2.205

Review 7.  HIV Persistence in Gut-Associated Lymphoid Tissues: Pharmacological Challenges and Opportunities.

Authors:  Corbin G Thompson; Cynthia L Gay; Angela D M Kashuba
Journal:  AIDS Res Hum Retroviruses       Date:  2017-05-16       Impact factor: 2.205

8.  Pathogenic consequences of vaginal infection with CCR5-tropic simian-human immunodeficiency virus SHIVSF162P3N.

Authors:  Madina Shakirzyanova; Lily Tsai; Wuze Ren; Agegneu Gettie; James Blanchard; Cecilia Cheng-Mayer
Journal:  J Virol       Date:  2012-06-27       Impact factor: 5.103

9.  Safety of excisional inguinal lymph node biopsies performed for research purposes in HIV-1-infected women and men.

Authors:  Amie L Meditz; Elizabeth Connick; Martin McCarter
Journal:  Surg Infect (Larchmt)       Date:  2014-05-09       Impact factor: 2.150

10.  Reactivation of HIV latency by a newly modified Ingenol derivative via protein kinase Cδ-NF-κB signaling.

Authors:  Guochun Jiang; Erica A Mendes; Philipp Kaiser; Sumathi Sankaran-Walters; Yuyang Tang; Mariana G Weber; Greg P Melcher; George R Thompson; Amilcar Tanuri; Luiz F Pianowski; Joseph K Wong; Satya Dandekar
Journal:  AIDS       Date:  2014-07-17       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.